Active substance
Tiagabine
- US FDA 6
- US price lines 3
- NHS prices 3
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| GABITRIL | 4MG; 12MG; 16MG; 2MG | tablet · oral | CEPHALON | Prescription | 30 Sep 1997 |
| TIAGABINE HYDROCHLORIDE | 2MG; 4MG; 12MG; 16MG | tablet · oral | MSN | Prescription | 16 Nov 2021 |
| GABITRIL | 20MG; 6MG; 8MG; 10MG | tablet · oral | CEPHALON | Discontinued | 30 Sep 1997 |
| TIAGABINE HYDROCHLORIDE | 2MG; 4MG | tablet · oral | SUN PHARM INDS | Discontinued | 4 Nov 2011 |
| TIAGABINE HYDROCHLORIDE | 2MG; 4MG; 12MG; 16MG | tablet · oral | WILSHIRE PHARMS INC | Discontinued | 13 Oct 2017 |
| TIAGABINE HYDROCHLORIDE | 2MG; 4MG; 12MG; 16MG | tablet · oral | AMNEAL PHARMS CO | Discontinued | 8 Dec 2017 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TIAGABINE HCL 12 MG TABLET | $6.61904 | per EA | 23 Sep 2026 |
| US NADAC | TIAGABINE HCL 2 MG TABLET | $2.62176 | per EA | 23 Sep 2026 |
| US NADAC | TIAGABINE HCL 4 MG TABLET | $2.52464 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tiagabine 10mg tablets | £104.09 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Tiagabine 15mg tablets | £156.13 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Tiagabine 5mg tablets | £52.04 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 9 Aug 2016 GABITRIL — safety-related labeling change
Labeling sections changed: Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.